Matches in SemOpenAlex for { <https://semopenalex.org/work/W2399335297> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W2399335297 endingPage "A61" @default.
- W2399335297 startingPage "A61" @default.
- W2399335297 abstract "To perform a cost-utility (CUA) and budget impact analysis (BIA) of oral dimethyl fumarate (DMF) in the Brazil’s Unified Health System (SUS). A Markov model was developed to simulate costs and outcomes of relapsing-remitting multiple sclerosis (RRMS) patients. Mutually exclusive health states were based on the Expanded Disability Status Scale (EDSS) score. Patients were initially distributed through EDSS states from 0-5 and could progress and/or relapse on yearly cycles. Treatment sequences were set in accordance with current local guidelines, starting with first-line interferon-beta 1a 22 mcg, 44 mcg or 30 mcg (IFN22, IFN44, IFN30), interferon-beta 1b 300 mcg (IFN300), glatiramer acetate (GLA) or DMF followed by second-line therapies natalizumab (NTZ) or fingolimod (FIN). Costs were obtained from SUS reimbursement lists and efficacy, safety/discontinuation parameters from a published literature systematic review. Results were expressed as incremental cost-utility ratios (ICUR). BIA was based on drug acquisition costs. Eligible population and current market-share distribution were estimated based on a public claims database (SIA/SUS). BIA’s results were presented on 3 different scenarios based on DMF market-share evolution after incorporation (low, moderate and high market penetration). DMF initiating sequences ending in NTZ and FIN, respectively, showed ICURs ranging from R$17,680 (US$4,568) to R$153,153 (US$39,575) and R$19,134 (US$4,947) to R$144,510 (US$37,341), respectively in comparison to other first-line options. Regarding effectiveness, DMF showed approximately 6.6 quality-adjusted life years (QALYs) compared to 6.1 (IFN22), 6.2 (IFN44), 6.2 (IFN30), 6.5 (IFN300) and 6.4 (GLA) QALYs. BIA results showed incremental cumulative costs ranging from R$2.1 to R$6.3 million (low and high market penetration scenarios, respectively) on a 5-year time horizon. DMF improves quality of life and is cost-effective under the Brazilian SUS perspective when compared to most of its comparators. Budget increments can be considered small (1-4%) in relation to current total MS drug expenditure in Brazil." @default.
- W2399335297 created "2016-06-24" @default.
- W2399335297 creator A5010024799 @default.
- W2399335297 creator A5010390942 @default.
- W2399335297 creator A5016560222 @default.
- W2399335297 creator A5037825072 @default.
- W2399335297 creator A5049139482 @default.
- W2399335297 date "2016-05-01" @default.
- W2399335297 modified "2023-09-26" @default.
- W2399335297 title "Cost-Utility Analysis of Dimethyl Fumarate as a First Switch Treatment for Relapsing Remitting Multiple Sclerosis in the Brazilian Public Health Care System" @default.
- W2399335297 doi "https://doi.org/10.1016/j.jval.2016.03.192" @default.
- W2399335297 hasPublicationYear "2016" @default.
- W2399335297 type Work @default.
- W2399335297 sameAs 2399335297 @default.
- W2399335297 citedByCount "0" @default.
- W2399335297 crossrefType "journal-article" @default.
- W2399335297 hasAuthorship W2399335297A5010024799 @default.
- W2399335297 hasAuthorship W2399335297A5010390942 @default.
- W2399335297 hasAuthorship W2399335297A5016560222 @default.
- W2399335297 hasAuthorship W2399335297A5037825072 @default.
- W2399335297 hasAuthorship W2399335297A5049139482 @default.
- W2399335297 hasBestOaLocation W23993352971 @default.
- W2399335297 hasConcept C126322002 @default.
- W2399335297 hasConcept C203014093 @default.
- W2399335297 hasConcept C2776036978 @default.
- W2399335297 hasConcept C2776819417 @default.
- W2399335297 hasConcept C2778577042 @default.
- W2399335297 hasConcept C2778715236 @default.
- W2399335297 hasConcept C2780640218 @default.
- W2399335297 hasConcept C2781004633 @default.
- W2399335297 hasConcept C2908647359 @default.
- W2399335297 hasConcept C3020694758 @default.
- W2399335297 hasConcept C71924100 @default.
- W2399335297 hasConcept C99454951 @default.
- W2399335297 hasConceptScore W2399335297C126322002 @default.
- W2399335297 hasConceptScore W2399335297C203014093 @default.
- W2399335297 hasConceptScore W2399335297C2776036978 @default.
- W2399335297 hasConceptScore W2399335297C2776819417 @default.
- W2399335297 hasConceptScore W2399335297C2778577042 @default.
- W2399335297 hasConceptScore W2399335297C2778715236 @default.
- W2399335297 hasConceptScore W2399335297C2780640218 @default.
- W2399335297 hasConceptScore W2399335297C2781004633 @default.
- W2399335297 hasConceptScore W2399335297C2908647359 @default.
- W2399335297 hasConceptScore W2399335297C3020694758 @default.
- W2399335297 hasConceptScore W2399335297C71924100 @default.
- W2399335297 hasConceptScore W2399335297C99454951 @default.
- W2399335297 hasIssue "3" @default.
- W2399335297 hasLocation W23993352971 @default.
- W2399335297 hasOpenAccess W2399335297 @default.
- W2399335297 hasPrimaryLocation W23993352971 @default.
- W2399335297 hasRelatedWork W1532617462 @default.
- W2399335297 hasRelatedWork W2059346471 @default.
- W2399335297 hasRelatedWork W2085438061 @default.
- W2399335297 hasRelatedWork W2179093540 @default.
- W2399335297 hasRelatedWork W2398000750 @default.
- W2399335297 hasRelatedWork W2963474248 @default.
- W2399335297 hasRelatedWork W3012381399 @default.
- W2399335297 hasRelatedWork W4214753683 @default.
- W2399335297 hasRelatedWork W4232904689 @default.
- W2399335297 hasRelatedWork W4292433363 @default.
- W2399335297 hasVolume "19" @default.
- W2399335297 isParatext "false" @default.
- W2399335297 isRetracted "false" @default.
- W2399335297 magId "2399335297" @default.
- W2399335297 workType "article" @default.